Processa Pharmaceuticals (PCSA) Current Assets (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Current Assets came in at $1.9 million in Q1 2026, down 48.42% YoY from $3.8 million in Q1 2025, and down 65.82% on a QoQ basis from $5.7 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Current Assets (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Current Assets data on file, last reported at $1.9 million in Q1 2026.
- Quarterly Current Assets fell 48.42% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 48.42% YoY) and the FY2025 annual result came in at $5.7 million, up 201.78% from the prior year.
- Current Assets slipped to $1.9 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $16.4 million in Q1 2022 to a low of $1.9 million in Q4 2024.
- A 5-year average of $7.9 million and a median of $7.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets sank 66.64% — and 2025, when it soared 201.78%.
- Tracing PCSA's Current Assets over 5 years: stood at $8.4 million in 2022, then slumped by 32.84% to $5.6 million in 2023, then slumped by 66.64% to $1.9 million in 2024, then soared by 201.78% to $5.7 million in 2025, then plunged by 65.82% to $1.9 million in 2026.
- The last three Current Assets figures came in at $1.9 million (Q1 2026), $5.7 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Processa Pharmaceuticals | 5.72 Mn | 5.72 Mn | - | 2.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.94 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 6.59 Mn |
| Jun 30, 2025 | 7.15 Mn |
| Mar 31, 2025 | 3.76 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Jun 30, 2024 | 7.48 Mn |
| Mar 31, 2024 | 9.80 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Sep 30, 2023 | 7.91 Mn |
| Jun 30, 2023 | 9.90 Mn |
| Mar 31, 2023 | 12.22 Mn |
| Dec 31, 2022 | 8.39 Mn |
| Sep 30, 2022 | 10.89 Mn |
| Jun 30, 2022 | 13.96 Mn |
| Mar 31, 2022 | 16.38 Mn |
| Dec 31, 2021 | 18.33 Mn |
| Sep 30, 2021 | 20.67 Mn |
| Jun 30, 2021 | 22.57 Mn |